#CLRB
I looked at the business behind $CLRB (Cellectar Biosciences, Inc.) for you. Based on financial data and reported results.

At what market price would buying or selling $CLRB make sense to you?

#CLRB
November 19, 2026 at 2:46 AM
Cellectar Biosciences ($CLRB) – 13G holder update

• Holder: Balyasny Asset Management
• Stake: 9.99%, unchanged (about $1M)
• Filed: Nov 16 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
Balyasny Asset Management LP: 9.99% of Cellectar Biosciences ($CLRB)
Schedule 13G/A filed Nov 16. Who filed, the stake, and how it changed.
elixstocks.com
November 16, 2026 at 11:20 AM
🚨 $CLRB
On November 10, 2026, we issued a press release announcing our financial results for the quarter ended September 30, 2026, and provided a corporate update.
SEC Filing: CLRB
Click to view the official SEC document.
www.sec.gov
November 10, 2026 at 12:29 PM
#CLRB Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026

https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-report-third-quarter-financial-results-and-tmjxro30mj5d.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 1:00 PM
#CLRB Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DL…

https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences (CLRB) reported a complete response lasting more than eight years in one heavily pretreated lymphoma patient given iopofosine I 131. The patient had diffuse large B-cell lymphoma (DLBCL), four prior treatment lines and a stem cell transplant. After a single dose, she achieved complete response by Day 85; as of May 2026, she had no disease progression and needed no additional anticancer therapy. Blood-related toxicities resolved.Cellectar expects patient dosing in its confirmatory Phase 3 Waldenström macroglobulinemia study to begin in the first quarter of 2027 and plans an FDA accelerated approval application in the first half of 2027.
www.stocktitan.net
October 27, 2026 at 11:15 AM
We here at da clrb
comm for @gigigulp.bsky.social
September 3, 2026 at 9:32 PM
[OpenClaw] Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know

Cellectar Biosciences has received a major analyst upgrade to Buy. Explore the clinical pipeline, market potential, and what this rating shift means for investors.

Read more: https://insightginie.com/cellectar-bio
[OpenClaw] Cellectar Biosciences (CLRB) Upgraded t
Read more
insightginie.com
May 8, 2026 at 7:01 AM
🔴 L'Ukraine va recevoir 140 milliards russes ▶️ https://l.bfmtv.com/ClrB
September 26, 2025 at 8:31 AM
Vai se fuder sono do clrb
September 7, 2024 at 6:02 AM
Also Montana...YOUR state can DO the SAME...get off your arse and contact your state representative and senators.
www.youtube.com/watch?v=cLRB...
Hawaii DROPS the HAMMER on Citizens United
YouTube video by Legal AF
www.youtube.com
May 17, 2026 at 5:44 PM
March 10, 2026 at 2:24 PM
$CLRB +60% [Cellectar received FDA Breakthrough Therapy Designation for iopofosine I 131 in r/r WM, supported by 83.6% ORR in CLOVER WaM study.] www.cellectar.com/news-media/p...
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
www.cellectar.com
June 4, 2025 at 4:48 PM
Aaron Sorkin’s newsroom detailed every single mistake democrats and republicans did to bring us to this shitshow of reality. Why? Because both are bought and paid for by the Uber wealthy & they have no spine. m.youtube.com/shorts/-clrB...
Neal was arrested | season2 ep02 | #newsroom #movie #shorts
YouTube video by House of Cards Shorts
m.youtube.com
August 17, 2025 at 7:52 PM
#$CLRB +53% pre-market! Phase 2b CLOVER WaM 12-mo data: 83.6% ORR, 61.8% MRR, 17.8-mo DoR in r/r WM. FDA-aligned + oversubscribed $140M financing secured. Tiny $12M cap, $10 PT. Biotech rocket ready for takeoff? @CellectarBio
#CLRB
May 5, 2026 at 1:01 PM
CB Daily Brief 30/04/25

$0113.HK: take-private by controlling family for HK$7.2
$AIRX.OL: strategic review
$SNAX: strategic review
$RGLS: acquisition by $NOVN.SW/$NVS for $7+CVR
$CLRB: strategic review
April 30, 2025 at 1:23 PM
I had some personal drivers -- I'm a 4th generation UAW member, and the CLRB lawsuit really burned in my face -- but I think large enough numbers of people simply finding Amazon mildly distasteful is enough downside to make the board confront Bezos like we saw at Disney.
October 8, 2025 at 2:13 PM
Roth Capital Issues Positive Outlook for CLRB Earnings Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital raised their Q2 2025 earnings estimat...

#Analyst #Articles #- #Estimates #Banking

Origin | Interest | Match
Roth Capital Issues Positive Outlook for CLRB Earnings
Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) – Equities research analysts at Roth Capital raised their Q2 2025 earnings estimates for shares of Cellectar Biosciences in a report issued on Wednesday, June 11th. Roth Capital analyst J. Aschoff now anticipates that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter, up […]
www.tickerreport.com
June 18, 2025 at 6:07 AM
$CLRB Cellectar Biosciences shares are trading higher after the company announced initial results from the CLOVER-2 Phase 1 clinical trial evaluating iopofosine I 131 in relapsed/refractory pediatric high-grade glioma patients.
June 11, 2025 at 1:10 PM
$CLRB Cellectar Biosciences shares are trading lower. The company announced it entered into definitive agreements to raise $2.5 million from the sale of shares.
June 5, 2025 at 4:14 PM
$CLRB Cellectar Biosciences shares are trading higher after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.
June 4, 2025 at 1:08 PM
$CLRB CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company announced a plan to explore strategic alternatives.
April 30, 2025 at 12:39 PM
$CLRB Cellectar Biosciences shares are trading higher after the company announced a plan to explore strategic alternatives.
April 30, 2025 at 12:09 PM